Impact ledger
SPDR S&P Biotech ETF (XBI)
34 events mapped to this ticker since 2026-06-15.
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-07-15 | Event | Increased investor sentiment and capital flow into the biotechnology sector, particularly for small to mid-cap oncology-focused companies, due to a successful regulatory approval. | Bullish | 1-5d | 0.40 |
| 2026-07-14 | Event | Increased funding for a biotech company, potentially signaling investor confidence in the broader biotech sector, especially in neurological disorders. | Bullish | 1-5d | 0.30 |
| 2026-07-14 | Event | Increased M&A activity, particularly licensing deals in the biotech sector, can signal a healthy environment for innovation and asset valuation, potentially leading to broader investor interest in biotech ETFs. However, the impact of a single deal on a diversified ETF is generally limited. | watch | 1-5d | 0.30 |
| 2026-07-08 | Event | General positive sentiment spillover for the biotechnology sector, particularly for companies with late-stage pipeline assets. | Bullish | 1-5d | 0.20 |
| 2026-07-04 | Event | General sentiment indicator for the biotech sector; large capital raises can signal investor confidence or, conversely, a need for cash in a challenging environment. | watch | 1-5d | 0.30 |
| 2026-06-30 | Event | Indirect beneficiary; increased M&A activity in the biotech sector, particularly for late-stage assets, tends to drive up valuations for companies within the ETF's holdings. | Bullish | 1-3m | 0.80 |
| 2026-06-30 | Event | Increased M&A activity, particularly for late-stage assets, directly benefits biotech companies, many of which are held in this ETF, leading to higher valuations and potential acquisition premiums. | Bullish | 1-3m | 0.80 |
| 2026-06-29 | Event | Potential for increased trading volume and minor rebalancing activity within the ETF as its underlying constituents (some of which may be new Russell additions) are adjusted. | watch | intraday | 0.40 |
| 2026-06-29 | Event | Indirect, minor impact on the broader biotechnology sector sentiment, particularly for small-cap or development-stage biotechs. Successful SPAC mergers can briefly boost sentiment. | watch | 1-5d | 0.10 |
| 2026-06-29 | Event | General sentiment towards biotech M&A, potential for similar deals, and the specific performance of ZYME and TBPH as components of the ETF. | watch | 1-3m | 0.30 |
| 2026-06-29 | Event | General sentiment towards biotech M&A, potential for sector-wide re-rating of similar assets. | watch | 1-3m | 0.20 |
| 2026-06-29 | Event | Positive sentiment spillover for the biotechnology sector, particularly for companies with advanced clinical pipelines and successful partnerships. | Bullish | 1-5d | 0.20 |
| 2026-06-25 | Event | Positive news for a small-cap biotech company, particularly related to intellectual property, can contribute to overall sentiment in the biotech sector, albeit with a minor impact on a broad ETF. | Bullish | 1-3m | 0.10 |
| 2026-06-25 | Event | Positive news from a constituent company, especially a clinical-stage biotech, can contribute to overall sector sentiment, albeit with a minor impact. | Bullish | 1-5d | 0.20 |
| 2026-06-24 | Event | Improved sentiment in the biotechnology sector due to positive clinical news from a constituent company, potentially leading to minor inflows or reduced selling pressure. | Bullish | 1-5d | 0.20 |
| 2026-06-24 | Event | Negative sentiment and potential selling pressure on the broader biotechnology sector due to a prominent bankruptcy, impacting ETF holdings. | Bearish | 1-5d | 0.40 |
| 2026-06-23 | Event | Positive sentiment for the broader biotechnology sector due to successful capital raise for a pre-clinical/early-clinical stage company, indicating investor confidence. | Bullish | 1-5d | 0.60 |
| 2026-06-23 | Event | A successful IPO in the biotech sector, especially one raising significant capital, can be seen as a positive signal for the broader industry, potentially boosting investor confidence in biotech ETFs. | Bullish | 1-5d | 0.30 |
| 2026-06-23 | Event | Successful IPOs can signal broader investor appetite for the biotechnology sector, potentially influencing sentiment for related ETFs. | watch | 1-5d | 0.20 |
| 2026-06-23 | Event | While one company's bankruptcy is negative, the acquisition by a large pharma company could signal ongoing M&A activity, which can be positive for the sector. | mixed | 1-5d | 0.10 |
| 2026-06-23 | Event | Minor negative sentiment spillover due to a constituent company's bankruptcy, potentially increasing risk aversion in the broader biotech sector. | Bearish | 1-5d | 0.20 |
| 2026-06-17 | Event | General sentiment in the biotechnology sector, particularly for small-cap clinical-stage companies. AZTR's capital conservation move could be seen as indicative of broader funding challenges or increased investor caution. | Bearish | 1-5d | 0.20 |
| 2026-06-16 | Event | Minor positive sentiment spillover from a constituent company's intellectual property news, but unlikely to significantly move the broad ETF. | watch | 1-5d | 0.10 |
| 2026-06-15 | Event | Sentiment spillover from a small-cap biotech company's significant restructuring, potentially indicating broader industry pressures. | watch | 1-3m | 0.20 |
| 2026-06-15 | Event | Minor sentiment spillover from a clinical trial failure within the biotech sector, particularly for smaller, development-stage companies. | Bearish | 1-5d | 0.10 |
| 2026-06-15 | Event | Negative sentiment spillover from a clinical trial failure in the biotech sector, particularly for small-cap oncology companies. | Bearish | 1-5d | 0.10 |
| 2026-06-15 | Event | General negative sentiment spillover to the broader biotechnology sector, particularly for clinical-stage companies. | Bearish | 1-5d | 0.20 |
| 2026-06-15 | Event | Negative sentiment spillover from a clinical trial failure in the small-cap biotech space. | Bearish | 1-5d | 0.10 |
| 2026-06-15 | Event | Sentiment spillover from a small-cap biotech company undergoing significant restructuring, potentially indicating broader sector challenges. | watch | 1-3m | 0.20 |
| 2026-06-15 | Event | Sentiment spillover from a struggling biotech company, potentially highlighting broader sector challenges. | watch | 1-3m | 0.20 |
| 2026-06-15 | Event | Indirect sentiment impact on the broader biotechnology sector, particularly for clinical-stage companies with single or limited late-stage assets. | Bearish | 1-5d | 0.20 |
| 2026-06-15 | Event | Sentiment spillover from a clinical trial failure in the biotech sector, particularly for a company focused on oncology, which can broadly affect investor perception of early-stage biotech. | Bearish | 1-5d | 0.20 |
| 2026-06-15 | Event | General positive sentiment spillover within the biotechnology sector, particularly for companies with pipeline progress. | watch | 1-5d | 0.10 |
| 2026-06-15 | Event | Positive sentiment spillover from a component company's regulatory milestone, potentially attracting broader investor interest in the biotech sector. | Bullish | 1-5d | 0.20 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for XBI, start a trial or view the XBI entity page.